0I7E.L Stock Analysis
0I
Avoid
Based on Eyestock quantitative analysis, 0I7E.L`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
DaVita, Inc. engages in the provision of medical care services. The company is headquartered in Denver, Colorado and currently employs 70,000 full-time employees. The firm provides kidney care services in the United States. The firm's operations are comprised of its U.S. dialysis and related lab services business (its U.S. dialysis business), its U.S. integrated kidney care business, its U.S. other ancillary services and its international operations (its ancillary services). The U.S. dialysis and related lab services (U.S. dialysis) business treats patients with chronic kidney failure, and end-stage kidney disease (ESKD). Its services include outpatient hemodialysis services, hospital inpatient hemodialysis services, and home-based dialysis services. The ancillary services consist of integrated kidney care services, physician services, clinical research programs, and transplant software business, as well as international operations. The firm operates approximately 2,724 outpatient dialysis centers in the United States.